ESMO 2023 | AZD7789 in NSCLC: safety, efficacy, and ongoing evaluation

Benjamin Besse, MD, PhD, Gustave Roussy, Villejuif, France, discusses an evaluation of the safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy in a Phase I/IIa clinical trial (NCT04931654). No dose-limiting toxicities were observed, and treatment-related adverse events were manageable, with no grade 3 or higher events. Preliminary efficacy was observed, with some patients experiencing stable disease or target lesion shrinkage. Higher doses of AZD7789 led to significant PD-1 receptor occupancy on peripheral T cells. Ongoing evaluation is underway in immunotherapy-naive NSCLC patients and those with acquired resistance to immunotherapy. Updated data will provide further insights into AZD7789’s potential. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.